COMPASS THERAPEUTICS, INC. Retained Earnings
COMPASS THERAPEUTICS, INC. (CMPX) had Retained Earnings of -$474.64 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$474.64M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$449.49M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$431.17M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$415.46M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$474.64M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | -$449.49M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | -$431.17M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | -$415.46M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | -$401.20M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | -$381.32M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | -$364.68M 10-K · filed 2026-03-05 | |
| 2024-09-30 | -$349.65M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$339.17M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | -$326.10M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | -$315.31M 10-K · filed 2025-02-27 | |
| 2023-09-30 | -$301.89M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | -$291.93M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | -$280.65M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | -$272.81M 10-K · filed 2024-03-21 | |
| 2022-09-30 | -$261.22M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | -$249.25M 10-Q · filed 2022-08-01 | |
| 2022-03-31 | -$240.75M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | -$233.59M 10-K · filed 2023-03-15 | |
| 2021-09-30 | -$220.61M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | -$214.63M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | -$158.83M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | -$151.41M 10-K · filed 2022-03-18 | |
| 2020-09-30 | -$143.02M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | -$133.87M 10-Q · filed 2020-08-13 | |
| 2020-03-31 | -$108.57K 10-K · filed 2020-06-08 | |
| 2019-12-31 | -$121.91M 10-K · filed 2021-03-05 | -$102.64K 10-Q · filed 2020-02-14 |
| 2019-09-30 | -$90.95K 10-Q · filed 2019-11-13 | |
| 2019-06-30 | -$82.55K 10-Q · filed 2019-08-13 | |
| 2019-03-31 | -$71.09K 10-K · filed 2020-06-08 | |
| 2018-12-31 | -$62.22K 10-Q · filed 2019-02-14 | |
| 2018-09-30 | -$52.08K 10-Q · filed 2018-11-14 | |
| 2018-06-30 | -$43.53K 10-Q · filed 2018-08-14 | |
| 2018-03-31 | -$35.05K 10-K · filed 2019-07-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |